Evusheld safety checked in japanese patients

NCT ID NCT05687877

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked how safe Evusheld is for treating and preventing COVID-19 in Japanese patients. It included 366 people who got the drug in real-world settings. The main goal was to track side effects like allergic reactions and heart problems. The study is now complete and helps confirm the drug's safety profile.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2 INFECTION

Contacts and locations

Locations

Research Site

Aichi, Japan
Research Site

Chiba, Japan
Research Site

Fukuoka, Japan
Research Site

Fukushima, Japan
Research Site

Hiroshima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Ibaraki, Japan
Research Site

Ishikawa, Japan
Research Site

Kagoshima, Japan
Research Site

Kanagawa, Japan
Research Site

Kyoto, Japan
Research Site

Mie, Japan
Research Site

Nara, Japan
Research Site

Numakunai, Japan
Research Site

Osaka, Japan
Research Site

Tokyo, Japan
Research Site

Tottori, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.